ARA-290 vs Livagen

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress. Published research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in aging tissue models and demonstrated peptide regulation of cell differentiation in progenitor populations, providing the class-level mechanistic context for livagen's proposed hepatic regulatory effects. Livagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.